Evidence map›Paper›PMID 41285709›Full record

ArticleNature communications2025

T

Hubert Tseng, Bhagirathbhai Dholaria, Stacey A Cranert, Maximilian Richter, Karl S Marquez, Benjamin S Cho, Andrew Bacong, Katherine McArthur, Jeff D Eskew, Joanne McCaigue and 16 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Hubert TsengPoseida Therapeutics, Inc, San Diego, CA, USA.
Bhagirathbhai DholariaDepartment of Medicine, Department of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-2371-3655
Stacey A CranertPoseida Therapeutics, Inc, San Diego, CA, USA.
Maximilian RichterPoseida Therapeutics, Inc, San Diego, CA, USA.
Karl S MarquezPoseida Therapeutics, Inc, San Diego, CA, USA.
Benjamin S ChoPoseida Therapeutics, Inc, San Diego, CA, USA.
Andrew BacongPoseida Therapeutics, Inc, San Diego, CA, USA.
Katherine McArthurPoseida Therapeutics, Inc, San Diego, CA, USA.
Jeff D EskewPoseida Therapeutics, Inc, San Diego, CA, USA.
Joanne McCaiguePoseida Therapeutics, Inc, San Diego, CA, USA.
Sabrina HaagPoseida Therapeutics, Inc, San Diego, CA, USA.
Aly KrasnyPoseida Therapeutics, Inc, San Diego, CA, USA.
Brian SoliminePoseida Therapeutics, Inc, San Diego, CA, USA.
Michael J CoffeyPoseida Therapeutics, Inc, San Diego, CA, USA.
Aimee LoyolaPoseida Therapeutics, Inc, San Diego, CA, USA.
Jasmine KwongPoseida Therapeutics, Inc, San Diego, CA, USA.
Leyla ShuneDivision of Hematological Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, KS, USA.
Andrew KinKarmanos Cancer Institute, Wayne State University, Detroit, MI, USA.ORCID http://orcid.org/0000-0002-3263-2374
Caitlin L CostelloMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Mehmet H KocogluMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, MD, USA.
Aravind RamakrishnanSarah Cannon Transplant and Cellular Therapy Program, St. David's South Austin Medical Center, Austin, TX, USA.
Hamid NaminiPoseida Therapeutics, Inc, San Diego, CA, USA.
Christopher E MartinPoseida Therapeutics, Inc, San Diego, CA, USA.
Rajesh BelaniPoseida Therapeutics, Inc, San Diego, CA, USA.
Julia CoronellaPoseida Therapeutics, Inc, San Diego, CA, USA.
Devon J ShedlockPoseida Therapeutics, Inc, San Diego, CA, USA. shedlocd@gene.com.ORCID http://orcid.org/0000-0003-1018-7510

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autologous CAR-T therapies targeting B-cell maturation antigen (BCMA) in relapsed/refractory multiple myeloma (RRMM) have demonstrated therapeutic clinical responses. Here, we present the characterization and interim Phase I data for P-BCMA-ALLO1, a T

Indexed as

B-Cell Maturation AntigenImmunotherapy, AdoptiveMultiple MyelomaReceptors, Chimeric AntigenAdultAgedAnimalsCD8-Positive T-LymphocytesFemaleHumansMaleMiceMiddle AgedTreatment OutcomeXenograft Model Antitumor AssaysB-Cell Maturation AntigenReceptors, Chimeric AntigenTNFRSF17 protein, human

Identifiers

PMID41285709
PMCPMC12644732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.